Abeona Therapeutics Inc. (ABEO)
Automate Your Wheel Strategy on ABEO
With Tiblio's Option Bot, you can configure your own wheel strategy including ABEO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABEO
- Rev/Share 0.0
- Book/Share 0.8316
- PB 7.7922
- Debt/Equity 0.5792
- CurrentRatio 4.9002
- ROIC -0.7722
- MktCap 331495416.0
- FreeCF/Share -1.2656
- PFCF -5.2617
- PE -7.3004
- Debt/Assets 0.2413
- DivYield 0
- ROE -0.8645
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 2
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | ABEO | Oppenheimer | -- | Outperform | -- | $19 | June 2, 2025 |
| Initiation | ABEO | Oppenheimer | -- | Outperform | -- | $16 | March 5, 2025 |
News
Abeona Therapeutics: Substantially Undervalued Post-FDA Approval (Rating Upgrade)
Published: June 05, 2025 by: Seeking Alpha
Sentiment: Positive
Abeona's ZEVASKYN approval and a $3.1 million price point are undervalued by the market, especially after a $152 million PRV sale bolstered cash reserves. Conservative launch modeling, including risk-adjusted revenue and single-treatment assumptions, still yields a fair value 36%+ above the current share price. Execution of outcome-based payer agreements and a strong cash position de-risk the launch, while competition and reimbursement remain manageable concerns.
Read More
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
CLEVELAND, June 02, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Read More
Abeona Therapeutics Inc. (ABEO) Q1 2025 Earnings Call Transcript
Published: May 16, 2025 by: Seeking Alpha
Sentiment: Neutral
Abeona Therapeutics Inc. (NASDAQ:ABEO ) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Greg Gin - Vice President-Investor Relations and Communications Vish Seshadri - Chief Executive Officer Madhav Vasanthavada - Chief Commercial Officer and Head-Business Development Brian Kevany - Chief Technical Officer Joe Vazzano - Chief Financial Officer Conference Call Participants Rick Miller - Cantor Fitzgerald Steven Willey - Stifel Ram Selvaraju - H.C. Wainwright James Molloy - Alliance Global Partners David Bautz - Zacks Small Cap Research Operator Good day and welcome to the Abeona Therapeutics First Quarter 2025 Conference Call.
Read More
Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
CLEVELAND, May 12, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $155 million upon the closing of the transaction. Abeona was awarded the PRV following the U.S. Food and Drug Administration (FDA) approval of ZEVASKYN™ (prademagene zamikeracel) on April 28, 2025.
Read More
US FDA approves Abeona's skin disorder therapy
Published: April 29, 2025 by: Reuters
Sentiment: Positive
The U.S. Food and Drug Administration on Tuesday approved Abeona Therapeutics' gene therapy for a rare skin disorder.
Read More
U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
- ZEVASKYN fills a critical need for people living with RDEB, a debilitating dermatological condition with no cure - - Approval based on the pivotal Phase 3 VIITAL™ study, showing ZEVASKYN resulted in significant wound healing and pain reduction after a single treatment with a favorable safety profile - - ZEVASKYN to be available through Qualified Treatment Centers beginning in 3Q 2025 - - Abeona Assist™ patient services program offers personalized support for eligible patients and families throughout their treatment journey with ZEVASKYN - - Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA - - Abeona Therapeutics ® …
Read More
Pz-Cel Has Massive Potential For RDEB Patients
Published: April 21, 2025 by: Seeking Alpha
Sentiment: Positive
Abeona's pz-cel gene therapy shows the most durable wound healing in RDEB patients with no treatment related severe adverse events. There have been no instances of Squamous Cell Carcinoma. The FDA's previous Complete Response Letter focused on manufacturing and control issues. Since those questions have been answered thoroughly, an approval is likely by April 29th. Pz-cel offers a durable, one-time treatment. This reduces long-term costs compared to VYJUVEK which requires ongoing weekly applications.
Read More
Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
FDA priority review of pz-cel Biologics License Application (BLA) progressing with Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025
Read More
Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference
Published: March 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
CLEVELAND, March 04, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona's Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., will present at the Leerink Partners Global Healthcare Conference in Miami, Florida on Monday, March 10, 2025 at 3:00 p.m.
Read More
About Abeona Therapeutics Inc. (ABEO)
- IPO Date 1980-09-19
- Website https://www.abeonatherapeutics.com
- Industry Biotechnology
- CEO Dr. Vishwas Seshadri M.B.A., Ph.D.
- Employees 136